Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308087 · ClinicalTrials.gov registry record · Phase 2
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00308087 is a Phase 2 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 75 participants.
The verdict
NCT00308087, a Phase 2 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.
Interventions
- DRUG Rituximab
- DRUG Sargramostim (Leukine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00308087
The ClinicalTrials.gov registry entry for NCT00308087 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00308087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00308087 about?
NCT00308087 is a clinical study titled "Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma". The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.
What is the current status of trial NCT00308087?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2006-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00308087?
The interventions under investigation include: Rituximab (DRUG), Sargramostim (Leukine) (DRUG).
Who is sponsoring clinical trial NCT00308087?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.